Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -15,805.06%.

  • Cytokinetics' EBITDA Margin rose 1748565.00% to -15,805.06% in Q3 2025 from the same period last year, while for Sep 2025 it was -887.97%, marking a year-over-year increase of 1682377.00%. This contributed to the annual value of -3,914.12% for FY2024, which is 302697.00% up from last year.
  • As of Q3 2025, Cytokinetics' EBITDA Margin stood at -15,805.06%, which was down 7,655.31% from -203.80% recorded in Q2 2025.
  • Cytokinetics' 5-year EBITDA Margin high stood at -23.29% for Q2 2022, and its period low was -57,751.41% during Q2 2024.
  • Its 3-year average for EBITDA Margin is -17,681.14%, with a median of -14,815.46% in 2023.
  • Per our database at Business Quant, Cytokinetics' EBITDA Margin tumbled by 4,293,595bps in 2024 and then skyrocketed by 5,754,761bps in 2025.
  • Cytokinetics' EBITDA Margin (Quarterly) stood at -57.19% in 2021, then tumbled by 686,212bps to -6,919.32% in 2022, then crashed by 121,657bps to -8,135.89% in 2023, then spiked by 711,583bps to -1,020.06% in 2024, then surged by 1,748,565bps to -15,805.06% in 2025.
  • Its EBITDA Margin stands at -15,805.06% for Q3 2025, versus -203.80% for Q2 2025 and -10,274.16% for Q1 2025.